Interleukin-4 promoter polymorphisms: A genetic prognostic factor for survival in metastatic renal cell carcinoma

Journal of Clinical Oncology

Volumn 25, Issue 7, 2007, Pages 845-851

  Kleinrath, Thomas ^a   Gassner, Christoph ^a   Lackner, Peter ^a   Thurnher, Martin ^a   Ramoner, Reinhold ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 4; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC RISK; GENOTYPE; HAPLOTYPE; HETEROZYGOSITY; HUMAN; INTERLEUKIN 4 GENE; KIDNEY CARCINOMA; KIF3A GENE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; GENETIC POLYMORPHISM; GENETICS; KIDNEY TUMOR; MIDDLE AGED;

CARCINOMA, RENAL CELL; FEMALE; HAPLOTYPES; HUMANS; INTERLEUKIN-10; INTERLEUKIN-4; KIDNEY NEOPLASMS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TRANSFORMING GROWTH FACTOR BETA1;

EID: 33947545950     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.8154     Document Type: Article

References (72)

1. Janzen NK, Kim HL, Figlin RA, et al: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30:843-852, 2003
2. Cohen HT, McGovern FJ: Renal-cell carcinoma. N Engl J Med 353:2477-2490, 2005
3. Thurnher M, Radmayr C, Hobisch A, et al: Tumor-infiltrating T lymphocytes from renal-cell carcinoma express B7-1 (CD80): T-cell expansion by T-T cell co-stimulation. Int J Cancer 62:559-564, 1995
4. Ikemoto S, Yoshida N, Narita K, et al: Role of tumor-associated macrophages in renal cell carcinoma. Oncol Rep 10:1843-1849, 2003
5. Thurnher M, Radmayr C, Ramoner R, et al: Human renal-cell carcinoma tissue contains dendritic cells. Int J Cancer 68:1-7, 1996
6. Ikemoto S, Narita K, Yoshida N, et al: Effects of tumor necrosis factor alpha in renal cell carcinoma. Oncol Rep 10:1947-1955, 2003
7. Alberti L, Thomachot MC, Bachelot T, et al: IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 111:653-661, 2004
8. Nanus DM, Pfeffer LM, Bander NH, et al: Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: Correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 50:4190-4194, 1990
9. Kuebler JP, Oberley TD, Meisner LF, et al: Effect of interferon alpha, interferon beta, and interferon gamma on the in vitro growth of human renal adenocarcinoma cells. Invest New Drugs 5:21-29, 1987
10. Cheon J, Chung DJ, Kim JJ, et al: Inhibitory effects of interleukin-4 on human renal cell carcinoma cells in vitro: In combination with interferon-alpha, tumor necrosis factor-alpha or interleukin-2. Int J Urol 3:196-201, 1996
11. Obiri NI, Hillman GG, Haas GP, et al: Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by interleukin-4. J Clin Invest 91:88-93, 1993
12. Yu SJ, Kim HS, Cho SW, et al: IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1. Exp Mol Med 36:372-379, 2004
13. Falkensammer C, Johrer K, Gander H, et al: IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: Implications for antitumor immune responses. Cancer Immunol Immunother 55:1228-1237, 2006
14. Obiri NI, Husain SR, Debinski W, et al: Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin Cancer Res 2:1743-1749, 1996
15. Margolin K, Aronson FR, Sznol M, et al: Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother Emphasis Tumor Immunol 15:147-153, 1994
16. Whitehead RP, Unger JM, Goodwin JW, et al: Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: A Southwest Oncology Group study. J Immunother 21:440-446, 1998
17. Whitehead RP, Lew D, Flanigan RC, et al: Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: A southwest oncology group study. J Immunother 25:352-358, 2002
18. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med 335:865-875, 1996
19. Bidwell JL, Wood NA, Morse HR, et al: Human cytokine gene nucleotide sequence alignments, 1998. Eur J Immunogenet 25:83-265, 1998
20. Bidwell JL, Wood NA, Morse HR, et al: Human cytokine gene nucleotide sequence alignments: Supplement 1. Eur J Immunogenet 26:135-223, 1999
21. Bidwell J, Keen L, Gallagher G, et al: Cytokine gene polymorphism in human disease: On-line databases. Genes Immun 1:3-19, 1999
22. Rao N, Nguyen S, Ngo K, et al: A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling. Mol Cell Biol 25:6521-6532, 2005
23. Linker-Israeli M, Wallace DJ, Prehn J, et al: Association of IL-6 gene alleles with systemic lupus erythematosus (SLE) and with elevated IL-6 expression. Genes Immun 1:45-52, 1999
24. Vandenbroeck K, Goris A: Cytokine gene polymorphisms in multifactorial diseases: Gateways to novel targets for immunotherapy? Trends Pharmacol Sci 24:284-289, 2003
25. Rosenwasser LJ, Klemm DJ, Dresback JK, et al: Promoter polymorphisms in the chromosome 5 gene cluster in asthma and atopy. Clin Exp Allergy 25 Suppl 2:74-78, 1995; discussion 95-96
26. Nakashima H, Miyake K, Inoue Y, et al: Association between IL-4 genotype and IL-4 production in the Japanese population. Genes Immun 3:107-109, 2002
27. Kabesch M, Tzotcheva I, Carr D, et al: A complete screening of the IL4 gene: Novel polymorphisms and their association with asthma and IgE in childhood. J Allergy Clin Immunol 112:893-898, 2003
28. Basehore MJ, Howard TD, Lange LA, et al: A comprehensive evaluation of IL4 variants in ethnically diverse populations: Association of total serum IgE levels and asthma in white subjects. J Allergy Clin Immunol 114:80-87, 2004
29. Holtl L, Ramoner R, Zelle-Rieser C, et al: Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother 54:663-670, 2005
30. Holtl L, Zelle-Rieser C, Gander H, et al: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8:3369-3376, 2002
31. Louie LG, Hartogensis WE, Jackman RP, et al: Mycobacterium tuberculosis/HIV-1 coinfection and disease: Role of human leukocyte antigen variation. J Infect Dis 189:1084-1090, 2004
32. Mytilineos J, Laux G, Opelz G: Relevance of IL10, TGFbeta1, TNFalpha, and IL4Ralpha gene polymorphisms in kidney transplantation: A collaborative transplant study report. Am J Transplant 4:1684-1690, 2004
33. Hunt PJ, Marshall SE, Weetman AP, et al: Cytokine gene polymorphisms in autoimmune thyroid disease. J Clin Endocrinol Metab 85:1984-1988, 2000
34. Mullighan CG, Marshall SE, Bunce M, et al: Variation in immunoregulatory genes determines the clinical phenotype of common variable immunodeficiency. Genes Immun 1:137-148, 1999
35. Hoffmann SC, Stanley EM, Darrin Cox E, et al: Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28- stimulated peripheral blood lymphocytes. Transplantation 72:1444-1450, 2001
36. Solovieva S, Leino-Arjas P, Saarela J, et al: Possible association of interleukin 1 gene locus polymorphisms with low back pain. Pain 109:8-19, 2004
37. Bergholdt R, Karlsen AE, Johannesen J, et al: Characterization of polymorphisms of an interleukin 1 receptor type 1 gene (IL1RI) promotor region (P2) and their relation to insulin-dependent diabetes mellitus (IDDM): The Danish Study Group of Diabetes in Childhood. Cytokine 7:727-733, 1995
38. den Dunnen JT, Antonarakis E: Human Genome Variation Society: Nomenclature for the description of sequence variations. http://www.hgvs.org/ mutnomen/index.html
39. Hefler LA, Ludwig E, Lebrecht A, et al: Polymorphisms of the interleukin-1 gene cluster and ovarian cancer. J Soc Gynecol Investig 9:386-390, 2002
40. El-Omar EM, Carrington M, Chow WH, et al: Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398-402, 2000
41. Hall SK, Perregaux DG, Gabel CA, et al: Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein. Arthritis Rheum 50:1976-1983, 2004
42. Maksymowych WP, Reeve JP, Reveille JD, et al: High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of- flight mass spectrometry. Arthritis Rheum 48:2011-2018, 2003
43. Matesanz F, Fedetz M, Leyva L, et al: Effects of the multiple sclerosis associated -330 promoter polymorphism in IL2 allelic expression. J Neuroimmunol 148:212-217, 2004
44. Rockman MV, Hahn MW, Soranzo N, et al: Positive selection on a human-specific transcription factor binding site regulating IL4 expression. Curr Biol 13:2118-2123, 2003
45. Caggana M, Walker K, Reilly AA, et al: Population-based studies reveal differences in the allelic frequencies of two functionally significant human interleukin-4 receptor polymorphisms in several ethnic groups. Genet Med 1:267-271, 1999
46. Fishman D, Faulds G, Jeffery R, et al: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376, 1998
47. Terry CF, Loukaci V, Green FR: Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 275:18138-18144, 2000
48. Shin HD, Winkler C, Stephens JC, et al: Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci U S A 97:14467-14472, 2000
49. Alamartine E, Berthoux P, Mariat C, et al: Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol 120:99-103, 2003
50. Hall MA, McGlinn E, Coakley G, et al: Genetic polymorphism of IL-12 p40 gene in immune-mediated disease. Genes Immun 1:219-224, 2000
51. Pravica V, Perrey C, Stevens A, et al: A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 61:863-866, 2000
52. Tzakas P, Wong BY, Logan AG, et al: Transforming growth factor beta-1 (TGFB1) and peak bone mass: Association between intragenic polymorphisms and quantitative ultrasound of the heel. BMC Musculoskelet Disord 6:29-39, 2005
53. Kim YJ, Lee HS, Yoon JH, et al: Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection. Hum Mol Genet 12:2541-2546, 2003
54. Lu CC, Sheu BS, Chen TW, et al: Host TNF-alpha-1031 and -863 promoter single nucleotide polymorphisms determine the risk of benign ulceration after H. pylori infection. Am J Gastroenterol 100:1274-1282, 2005
55. The International HapMap Project: http://www.hapmap.org. Nature 426:789-796, 2003
56. Lo YM, Patel P, Newton CR, et al: Direct haplotype determination by double ARMS: Specificity, sensitivity and genetic applications. Nucleic Acids Res 19:3561-3567, 1991
57. Hardy G: Mendelian proportions in a mixed population. Science 28:49-50, 1908
58. Benjamini Y, Drai D, Elmer G, et al: Controlling the false discovery rate in behavior genetics research. Behav Brain Res 125:279-284, 2001
59. Sauerbrei W, Schumacher M: A bootstrap resampling procedure for model building: Application to the Cox regression model. Stat Med 11:2093-2109, 1992
60. Beghé B, Barton S, Rorke S, et al: Polymorphisms in the interleukin-4 and interleukin-4 receptor alpha chain genes confer susceptibility to asthma and atopy in a Caucasian population. Clin Exp Allergy 33:1111-1117, 2003
61. Modi WS, O'Brien TR, Vlahov D, et al: Haplotype diversity in the interleukin-4 gene is not associated with HIV-1 transmission and AIDS progression. Immunogenetics 55:157-164, 2003
62. Ries LAG, Eisner MP, Kosary CL, et al: National Cancer Institute: SEER Cancer Statistics Review, 1975-2002. http://seer.cancer.gov/csr/1975_2002/
63. Vale RD: The molecular motor toolbox for intracellular transport. Cell 112:467-480, 2003
64. Yanagawa T, Watanabe H, Takeuchi T, et al: Overexpression of autocrine motility factor in metastatic tumor cells: Possible association with augmented expression of KIF3A and GDI-beta. Lab Invest 84:513-522, 2004
65. Lin F, Hiesberger T, Cordes K, et al: Kidney-specific inactivation of the KIF3A subunit of kinesin-II inhibits renal ciliogenesis and produces polycystic kidney disease. Proc Natl Acad Sci U S A 100:5286-5291, 2003
66. Nelms K, Keegan AD, Zamorano J, et al: The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 17:701-738, 1999
67. Banchereau J, Briere F, Galizzi JP, et al: Human interleukin 4. J Lipid Mediat Cell Signal 9:43-53, 1994
68. Zisman A, Pantuck AJ, Dorey F, et al: Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19:1649-1657, 2001
69. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
70. Motzer RJ, Mazumdar M, Bacik J, et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530-2540, 1999
71. Motzer RJ, Bacik J, Schwartz LH, et al: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454-463, 2004
72. Negrier S, Perol D, Menetrier-Caux C, et al: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol 22:2371-2378, 2004